News

Clinical Trials Arena23h
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...